Nearly four thousand researchers attending a Vancouver conference on Alzheimer’s disease have released promising results for people in the early stages of memory loss.
A three-year study involving immunotherapy called I-V-I-G (intravenus immunoglobulin) has produced evidence of no decline in patients since they developed signs of Alzheimer’s, something the lead researcher is calling ‘remarkable.’
Doctor Norman Relkin says all 21 participants are in the same shape now they were in 36-months ago.
“To put this in perspective. when we see patients in our clinic with Alzheimer’s disease who are untreated, there’s usually measurable decline below baseline within three to six months. this is an unexpected finding.”
Relkin says side effects include an increased risk of stroke, rashes, chills and fever, but nothing unusual.
About The Reporter
